Show simple item record

dc.contributor.authorSingh, MN
dc.contributor.authorStringfellow, HF
dc.contributor.authorWalsh, MJ
dc.contributor.authorAshton, KM
dc.contributor.authorParaskevaidis, E
dc.contributor.authorAbdo, KR
dc.contributor.authorMartin-Hirsch, PL
dc.contributor.authorPhillips, DH
dc.contributor.authorMartin, FL
dc.date.accessioned2018-08-30T13:40:50Z
dc.date.issued2008-07-10
dc.identifier1
dc.identifier.citationTOXICOLOGY, 2008, 249 pp. 85 - 90
dc.identifier.issn0300-483X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2439
dc.identifier.doi10.1016/j.tox.2008.04.009
dc.description.abstractTamoxifen has been used in the management of receptor-positive breast cancer for >20 years. Usage confers an elevated risk of developing endometrial carcinoma. Its mechanism of carcinogenicity remains unresolved with controversy as to whether or not this is mediated through a genotoxic mechanism. Usage is not only associated with an elevated occurrence of endometrioid endometrial carcinoma, but also type 2 and mixed epithelial-stromal tumours (MESTs) that have a poorer prognosis. Following hysterectomy, endometrial tissues (n = 18) classified as benign (n = 6), non-tamoxifen-associated carcinoma (n = 6) and tamoxifen-associated carcinoma (n = 6) were obtained; quantitative gene expression was performed. Employing real-time RT-PCR, the relative gene expressions of phase I/II metabolic enzymes CYP1A2, CYP1B1 and CYP3A4, cathechol-O-methyltransferase (COMT) and SULT2A1 were ascertained. Measurable mRNA transcripts, especially for those genes associated with tamoxifen bioactivation, were quantifiable in all the tissues examined. Whether this is evidence that generation of genotoxic tamoxifen metabolites may occur in human endometrial tissue remains to be ascertained. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
dc.format.extent85 - 90
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER IRELAND LTD
dc.titleQuantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.tox.2008.04.009
rioxxterms.licenseref.startdate2008-07-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfTOXICOLOGY
pubs.notesaffiliation: Martin, FL (Reprint Author), Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England. Singh, Maneesh N.; Walsh, Michael J.; Martin, Francis L., Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England. Singh, Maneesh N.; Stringfellow, Helen F.; Ashton, Kate M.; Abdo, Khalil R.; Martin-Hirsch, Pierre L., Lancashire Teaching Hosp NHS Trust, Preston, Lancs, England. Paraskevaidis, Evangelos, Univ Ioannina, Dept Obstet & Gynaecol, GR-45110 Ioannina, Greece. Phillips, David H., Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England. keywords: CYP3A4; endometrial carcinoma; genotoxic; selective oestrogen receptor modulator; SULT2A1; tamoxifen keywords-plus: BREAST-CANCER PATIENTS; SURGICAL ADJUVANT BREAST; RAT-LIVER CELLS; DNA-ADDUCTS; ALPHA-HYDROXYTAMOXIFEN; RISK; THERAPY; EXPRESSION; ESTROGENS; ACTIVATION research-areas: Pharmacology & Pharmacy; Toxicology web-of-science-categories: Pharmacology & Pharmacy; Toxicology author-email: [email protected] orcid-numbers: L Martin, Francis/0000-0001-8562-4944 Phillips, David/0000-0001-8509-3485 number-of-cited-references: 50 times-cited: 17 usage-count-last-180-days: 0 usage-count-since-2013: 1 journal-iso: Toxicology doc-delivery-number: 325RU unique-id: ISI:000257606800012 da: 2018-08-30
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Human Biomonitoring & Carcinogen Activation
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Human Biomonitoring & Carcinogen Activation
pubs.volume249
pubs.embargo.termsNot known
icr.researchteamHuman Biomonitoring & Carcinogen Activationen_US
dc.contributor.icrauthorPhillips, David Hunteren


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record